National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom

International Journal of Cardiology

Volumn 91, Issue 2-3, 2003, Pages 163-172

  Bakhai, Ameet ^a,b   Flather, Marcus D ^a,b   Collinson, Julian R ^a   Stevens, Warren ^c   Normand, Charles ^c   Alemao, Evo ^d   Itzler, Robbin ^e   Ben Joseph, Rami ^e  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d RUTGERS UNIVERSITY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Acute coronary syndromes; Aggrastat; Cost effectiveness; Economic analysis; Glycoprotein IIb IIIa antagonists; Risk stratification

Indexed keywords

HEPARIN; TIROFIBAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; ECG ABNORMALITY; ELECTROCARDIOGRAM; FEMALE; HEALTH CARE COST; HEART BUNDLE BRANCH BLOCK; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; RISK REDUCTION; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ELECTROCARDIOGRAPHY; FEMALE; GREAT BRITAIN; HEART CATHETERIZATION; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT ADMISSION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SYNDROME; TREATMENT OUTCOME; TYROSINE;

EID: 1642324434     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(03)00023-8     Document Type: Article

References (19)

1. Collinson J., Flather M.D., Fox K.A.A., et al. for the PRAIS-UK Investigators Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J. 21:2000;1450-1457.
2. Klootwijk P., Hamm C. Acute coronary syndromes: diagnosis. Lancet. 353:(Suppl II):1999;10-15.
3. National Service Framework on Coronary Heart Disease: http://www.doh.gov.uk/pdfs/chdnsf.pdf
4. Topol E.J., Byzova T.V., Plow E.F. Platelet glycoprotein IIb-IIIa blockers. Lancet. 353:1999;227-231.
5. RA, Moliterno DJ, White H, Simoons, ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lance, 2002 Jul. 27; 360 (9329) 342-343.
6. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. New Engl J Med 1998;338(21):1488-1497.
7. Bertrand M.E., Simoons M.L., Fox K.A.A., et al. Management of acute coronary syndromes: acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 23:(23):2002;1809-1840.
8. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 40:(7):2002;1366-1374.
9. Guideline for the management of patients with acute coronary syndromes without persistent electrocardiogram ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit. Heart 2001;85:133-142.
10. NICE guidance on Gp IIb/IIIa inhibitors in the management of acute coronary syndromes: http://www.nice.org.uk/pdf/Nice+GLYCOPROTEIN+12+guidan.pdf
11. CASPE Research Case Mix Bulletin No 32 (1994).
12. Mark D.B., Harrington R.A., Lincoff A.M., et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation. 101:2000;366-371.
13. Szucs T.D., Meyer B.J., Kiowski W. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. Eur Heart J. 20:(17):2000;1253-1260.
14. Fox K.A.A., Cokkinos D.V., Deckers J., Keil U., Maggioni A., Steg G. The ENACT study: a pan-European survey of acute coronary syndromes. Eur Heart J. 21:1999;1440-1449.
15. Windecker S., Maier-Rudolph W., Bonzel T., et al. Interventional cardiology in Europe 1995. Working Group Coronary Circulation of the European Society of Cardiology. Eur Heart J. 20:1999;484-495.
16. Weintraub W.S., Thompson T.D., Culler S., et al. Targeting patients undergoing angioplasty for thrombus inhibition. A cost-effectiveness and decision support model. Circulation. 102:2000;392-398.
17. Palmer S, Sculpher M, Philips Z et al. A cost-effectiveness model comparing alternative management strategies for the use of glycoprotein IIb/ IIIa antagonists in non-ST-elevation acute coronary syndrome. Last accessed August 1st, 2002: http://www.nice.org.uk/pdf/glycoproteinmodelreport.pdf.
18. Topol E.J., Moliterno D.J., Herrmann H.C., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New Engl J Med. 344:(25):2001;1888-1894.
19. Stone G.W., Moliterno D.J., Bertrand M., et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Circulation. 105:(20):2002;2347-2354.